When is infliximab indicated in the treatment of Crohn disease?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print

Infliximab is a chimeric mouse-human monoclonal antibody against TNF-α that has shown promise in Crohn disease treatment; it blocks TNF-α in the serum and at the cell surface, leading to the lysis of TNF-producing macrophages and T cells. Infliximab has also been approved for the treatment of pediatric Crohn disease.

According to the American Gastroenterological Association (AGA), infliximab is indicated for the following:

  • Treatment of patients with Crohn disease who do not achieve adequate clinical response despite treatment with conventional therapy (ie, a corticosteroid or an immunosuppressive agent)

  • Treatment of fistulizing Crohn disease that is refractory to conventional therapy (ie, antibiotics, surgical drainage with examination under anesthesia, immunosuppressive therapy, or combinations thereof) [94]

Patients who respond to induction therapy with infliximab should receive maintenance therapy. [94]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!